Get the latest news and blog posts from APCI, including press releases and articles about advocacy actions, industry happenings, clinical pharmacy information, independent pharmacy operations, and much more.
BESSEMER, Ala. (Sept. 20) – A judge’s decision to allow the merger between UnitedHealth Group and Change Healthcare to move forward is likely to prove detrimental to patients, providers, and… Read More »
APCI warns that while Congress’s drug pricing proposals make progress, they fall short by failing to address the root problem: anti-competitive PBM practices driving costs and limiting patient access.
APCI urges federal regulators to block Prime Therapeutics’ acquisition of Magellan Rx, warning it would reduce competition and worsen prescription drug pricing and access.
APCI applauds the FTC’s unanimous decision to launch a sweeping investigation into PBM practices, marking a major step toward transparency and accountability in drug pricing.
APCI urges the FTC to investigate PBM practices, citing widespread anti-competitive behavior that drives up drug costs and limits patient access.
APCI challenges claims that Medicaid payment parity would cost $1 billion in New York, arguing the true figure is far lower and urging transparency around the state’s analysis.
A new study reveals how PBMs and Part D plans increase drug costs for seniors through misaligned incentives and fees, while outlining a path to save patients billions.
APCI backs the DOJ’s move to block UnitedHealth’s acquisition of Change Healthcare, citing risks to competition, patient choice, and prescription drug pricing.
After an FTC deadlock stalls a probe into PBM practices, APCI vows to keep pushing for transparency and accountability in prescription drug pricing.
APCI warns Congress is missing a key chance to curb PBM spread pricing and reform Medicaid managed care, leaving taxpayers, patients, and community pharmacies to bear the cost.